Trials / Completed
CompletedNCT01931033
An Open-Label Trial of Oxytocin in Adolescents With Autism Spectrum Disorders
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Massachusetts General Hospital · Academic / Other
- Sex
- All
- Age
- 11 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
This study is an 8-week open-label trial testing oxytocin nasal spray (Syntocinon) as a treatment for social impairment in adolescents with autism spectrum disorders (ASD). We hypothesize that oxytocin nasal spray will be safe, tolerable, and effective in improving the core symptoms of autism spectrum disorders in adolescents ages 11-17.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Intranasal Oxytocin |
Timeline
- Start date
- 2013-10-01
- Primary completion
- 2016-02-22
- Completion
- 2016-02-22
- First posted
- 2013-08-29
- Last updated
- 2024-07-01
- Results posted
- 2023-10-04
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01931033. Inclusion in this directory is not an endorsement.